About Company
__24I19GKAGK.jpg)
About Xantho Bio.
Founded in 2014, Xantho Biotechnology is dedicated to the development of botanical new drugs with low side effects from naturally derived materials, with the aim of providing new medications with improved clinical efficacy and to those with unmet medical needs. We are targeting at the botanical drug market with a global market size worth more than 40 billion USD.
*Botanical New Drug*
The main therapeutic area we are focusing on is dermatology. With the aim of improving the quality of life for patients, we develop products with market profitability and improved clinical effectiveness for patients in different age groups, thereby contributing to the well-being of human.
*Immunity and Inflammation*
The botanical new drug GM-XANTHO, a topical drug developed by Xantho Bio., is now in phase 2 study for atopic dermatitis (AD). The clinical data for the phase 2 study is expected to be available in Q1 2025. GM-XANTHO is shown to be safe and well-tolerated in human, and it is expected to be more accessible to AD patients compared to injectables and oral drugs.